Matches in SemOpenAlex for { <https://semopenalex.org/work/W2073938584> ?p ?o ?g. }
- W2073938584 endingPage "648" @default.
- W2073938584 startingPage "642" @default.
- W2073938584 abstract "We conducted a phase II, noncomparative, open-label, multicenter GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) study (CLL0809) to assess the efficacy and safety of bendamustine in combination with ofatumumab (BendOfa) in relapsed/refractory chronic lymphocytic leukemia (CLL). Forty-seven patients from 14 centers were evaluated. Therapy consisted of bendamustine (70 mg/m2) for 2 consecutive days every 28 days, and ofatumumab 300 mg on day 1 and 1000 mg on day 8 during the first cycle, and 1000 mg on day 1 subsequently. Treatment was administered up to six cycles. The overall response rate (ORR), as per intention-to-treat analysis, was 72.3% (95% confidence of interval (CI), 57–84%), with 17% complete responses. After a median follow-up of 24.2 months, the overall survival was 83.6% (95% CI, 73.0–95.7%) and the progression-free survival (PFS) was 49.6% (95% CI, 35.9–68.6%). The median PFS was 23.6 months. Univariate and multivariate analyses were used to identify clinical and biological characteristics associated with ORR and PFS. Myelosuppression was the most common toxicity; grade ⩾3 neutropenia was observed in 61.7% of patients; however, grade ⩾3 infections occurred in 6% of patients. BendOfa is feasible and effective in relapsed/refractory CLL patients, including patients with high-risk clinical and biological features." @default.
- W2073938584 created "2016-06-24" @default.
- W2073938584 creator A5009431453 @default.
- W2073938584 creator A5010723896 @default.
- W2073938584 creator A5012535656 @default.
- W2073938584 creator A5013362684 @default.
- W2073938584 creator A5015790909 @default.
- W2073938584 creator A5022153283 @default.
- W2073938584 creator A5027648948 @default.
- W2073938584 creator A5030806032 @default.
- W2073938584 creator A5038163660 @default.
- W2073938584 creator A5039006383 @default.
- W2073938584 creator A5041966654 @default.
- W2073938584 creator A5042629318 @default.
- W2073938584 creator A5047961182 @default.
- W2073938584 creator A5049135933 @default.
- W2073938584 creator A5058553911 @default.
- W2073938584 creator A5059658378 @default.
- W2073938584 creator A5062047451 @default.
- W2073938584 creator A5063235996 @default.
- W2073938584 creator A5063805789 @default.
- W2073938584 creator A5069596141 @default.
- W2073938584 creator A5070924011 @default.
- W2073938584 creator A5078192708 @default.
- W2073938584 creator A5078922292 @default.
- W2073938584 creator A5080861890 @default.
- W2073938584 creator A5086743021 @default.
- W2073938584 creator A5091664535 @default.
- W2073938584 date "2013-11-13" @default.
- W2073938584 modified "2023-10-18" @default.
- W2073938584 title "Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial" @default.
- W2073938584 cites W1243376384 @default.
- W2073938584 cites W1980260104 @default.
- W2073938584 cites W1993355130 @default.
- W2073938584 cites W1996452057 @default.
- W2073938584 cites W1999233413 @default.
- W2073938584 cites W2001850157 @default.
- W2073938584 cites W2004923784 @default.
- W2073938584 cites W2017723771 @default.
- W2073938584 cites W2029409133 @default.
- W2073938584 cites W2043415097 @default.
- W2073938584 cites W2049353008 @default.
- W2073938584 cites W2082312121 @default.
- W2073938584 cites W2086637735 @default.
- W2073938584 cites W2117648265 @default.
- W2073938584 cites W2124575836 @default.
- W2073938584 cites W2126442701 @default.
- W2073938584 cites W2135270635 @default.
- W2073938584 cites W2140606816 @default.
- W2073938584 cites W2142099365 @default.
- W2073938584 cites W2149515595 @default.
- W2073938584 cites W2151177887 @default.
- W2073938584 cites W2156824251 @default.
- W2073938584 cites W2163348695 @default.
- W2073938584 cites W2169269721 @default.
- W2073938584 cites W2318933236 @default.
- W2073938584 cites W2323897083 @default.
- W2073938584 cites W2326175431 @default.
- W2073938584 cites W4376595664 @default.
- W2073938584 doi "https://doi.org/10.1038/leu.2013.334" @default.
- W2073938584 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24220274" @default.
- W2073938584 hasPublicationYear "2013" @default.
- W2073938584 type Work @default.
- W2073938584 sameAs 2073938584 @default.
- W2073938584 citedByCount "56" @default.
- W2073938584 countsByYear W20739385842014 @default.
- W2073938584 countsByYear W20739385842015 @default.
- W2073938584 countsByYear W20739385842016 @default.
- W2073938584 countsByYear W20739385842017 @default.
- W2073938584 countsByYear W20739385842018 @default.
- W2073938584 countsByYear W20739385842019 @default.
- W2073938584 countsByYear W20739385842020 @default.
- W2073938584 countsByYear W20739385842022 @default.
- W2073938584 crossrefType "journal-article" @default.
- W2073938584 hasAuthorship W2073938584A5009431453 @default.
- W2073938584 hasAuthorship W2073938584A5010723896 @default.
- W2073938584 hasAuthorship W2073938584A5012535656 @default.
- W2073938584 hasAuthorship W2073938584A5013362684 @default.
- W2073938584 hasAuthorship W2073938584A5015790909 @default.
- W2073938584 hasAuthorship W2073938584A5022153283 @default.
- W2073938584 hasAuthorship W2073938584A5027648948 @default.
- W2073938584 hasAuthorship W2073938584A5030806032 @default.
- W2073938584 hasAuthorship W2073938584A5038163660 @default.
- W2073938584 hasAuthorship W2073938584A5039006383 @default.
- W2073938584 hasAuthorship W2073938584A5041966654 @default.
- W2073938584 hasAuthorship W2073938584A5042629318 @default.
- W2073938584 hasAuthorship W2073938584A5047961182 @default.
- W2073938584 hasAuthorship W2073938584A5049135933 @default.
- W2073938584 hasAuthorship W2073938584A5058553911 @default.
- W2073938584 hasAuthorship W2073938584A5059658378 @default.
- W2073938584 hasAuthorship W2073938584A5062047451 @default.
- W2073938584 hasAuthorship W2073938584A5063235996 @default.
- W2073938584 hasAuthorship W2073938584A5063805789 @default.
- W2073938584 hasAuthorship W2073938584A5069596141 @default.
- W2073938584 hasAuthorship W2073938584A5070924011 @default.
- W2073938584 hasAuthorship W2073938584A5078192708 @default.
- W2073938584 hasAuthorship W2073938584A5078922292 @default.
- W2073938584 hasAuthorship W2073938584A5080861890 @default.